TE TENX Tenax Therapeutics, Inc. Loading... : Bullish and Bearish Analyst Opinions

Author discloses existing long position in TENX, expressing desire for larger exposure within the broader XBI bullish thesis of macro tailwinds and record sector M&A.

Long TENX into topline LEVEL trial readout (expected August, before ESC abstracts) for oral levosimendan in PH-HFpEF; author argues levo's K-ATP venodilation mechanism uniquely addresses wedge pressure — the disease's defining lesion — where all prior drugs failed, with +300% upside vs -80% downside in a zero-approved-therapy multibillion market.

Buy TENX ahead of LEVEL-1 Phase 3 readout for levosimendan in PH-HFpEF; author models conditional power ≥85% at a clinically meaningful 20m 6MWD effect, CADENCE trial validates hemodynamic translation, FDA safety database already cleared for filing, and a positive read likely triggers M&A takeout well before LEVEL-2 (2028) — author discloses existing position.

Buy TENX ahead of August 2026 LEVEL trial topline; author argues oral levosimendan's K-ATP venodilation uniquely decongests PH-HFpEF without inotropy — the mechanism prior failures lacked — and that HELP's hemodynamic miss was a drug-trough timing artifact, not a true signal, creating a significant consensus mispricing in a zero-approved-therapy market.

Adam May speculates that TENX could either significantly outperform or underperform next quarter, expressing uncertainty rather than a clear directional call.

The author questions the clinical efficacy and dose-response data of Merck's sotatercept, suggesting potential overvaluation.

Reports full enrollment for a TENX clinical trial with data anticipated in Q3, providing a clear catalyst timeline without expressing a directional view.

Reports a 10% stake disclosure by Logos Capital in TENX; no directional view from speaker.

Long TENX as AZN's relaxin mAb pipeline removal narrows the competitive field to just TENX and MRK, with MRK focused on a narrow population — improving TENX's relative positioning in the relaxin space.

Buy TENX ahead of Q3 Phase 3 readout in PH-HFpEF — a 1.4M-patient indication with zero approved drugs; oral TID dosing in P3 corrects the drug-exposure flaw that weakened P2's 6MWT signal, KOL anecdotes are unusually strong, and market appears to undervalue probability of success relative to the massive TAM upside (analyst cites MRK gaining $8-10B on a weaker P2 hemodynamic endpoint in a smaller patient subset).

Buy TENX despite a seemingly lucky P2 6MWT result (29m drug-vs-placebo delta driven partly by unusual placebo decline); author argues bull case rests on PK/PD nuance, KOL/PI commentary, and asymmetric upside skew at current valuation.

Buy TENX ahead of a heavily underappreciated 2026 binary data readout; author is currently long and expects to hold through the catalyst, which they believe the market has not yet priced in.

TENX cited as a competing upside biotech catalyst in a 2026 contest context; no directional commitment from author, mentioned as a rival scenario.